PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug Q702 aims to boost immune system against blood cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called Q702 in people with certain blood cancers or related diseases that have not responded to other treatments. The drug works by helping the immune system attack cancer cells and supporting normal blood cell production. The study will ch…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 05:44 UTC
-
Promising new cocktail for brain cancer patients
Disease control Recruiting nowThis study is for people newly diagnosed with primary central nervous system lymphoma (PCNSL), a rare brain cancer. It tests a combination of four drugs (methotrexate, rituximab, sintilimab, and pirtobrutinib) to see if it works better than standard treatments. About 110 adults w…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated May 17, 2026 05:37 UTC
-
New drug combo targets brain lymphoma in early trial
Disease control Recruiting nowThis early-phase trial tests the safety of a drug called glofitamab, given after a pre-treatment with obinutuzumab, for people with central nervous system (CNS) lymphoma. The study enrolls 20 adults with primary or secondary CNS lymphoma. The goal is to see if this combination is…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for hard-to-treat brain cancer: drug duo targets relapsed lymphoma
Disease control Recruiting nowThis study tests a combination of two drugs, zanubrutinib and pemetrexed, in people whose central nervous system lymphoma has returned or not responded to prior treatment. The goal is to see if this approach can shrink tumors and control the disease. About 15 participants will re…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug cocktail shows promise for Hard-to-Treat brain cancer
Disease control Recruiting nowThis study tests a combination of three drugs (pembrolizumab, ibrutinib, and rituximab) in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if the combo can control the cancer for at least 6 months. About 3…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for brain cancer: immunotherapy plus chemo tested in small trial
Disease control Recruiting nowThis early-phase study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy is safe and effective for people newly diagnosed with primary central nervous system lymphoma, a rare brain cancer. About 15 participants will receive the combination and be …
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New drug cocktail takes on recurrent brain cancer
Disease control Recruiting nowThis early-phase trial is testing whether combining two drugs, epcoritamab and ibrutinib, is safe for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment. About 26 adults with this rare brain cancer will take part. The main goal is t…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:15 UTC